Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...

Amylin therapies are considered the next generation of obesity medication from the current GLP-1 products sold by Danish drug ...

Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

When a stock is in a freefall, there's usually a justifiable reason for the decline. But for investors with a high risk ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

Novo Nordisk (NVO) shares stumble after the results of the drugmaker's weight loss drug trial showed that patients using the drug dropped only around 15% of their weight, compared to the 25% that was ...

Doctor, doctor, give me the news, Hims & Hers Health (HIMS) has got bad case of the stock market blues ... up competition involving weight-loss drugs. The Food and Drug Administration two years ...

Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...